A Phase 3 interventional study of Tramadol HCl/Acetaminophen ER and Tramadol HCl/Acetaminophen IR in Pain, Postoperative, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-06-20.
Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing tramadol in Pain, Postoperative — 3 open to participants now, 5 under way, none of them phase 3. Tramadol · Pain, Postoperative.
Among the 34 studies testing tramadol in Pain, Postoperative, this one is the 7th largest by enrollment, is one of 3 that started in 2009, is one of 3 in phase 3, and was the 9th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →3 of the 34 studies testing tramadol in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–80
University of Thessaly · Sites in Greece
Ages 18–80
Arzu Esen Tekeli · Sites in Turkey
Ages 18–65
By country, each count listing its studies:
Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 25 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5 · Phase 4 16
First in 2002; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 320 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 93 across the 34 interventional studies. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Korea, Ltd., Korea, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.
18 studies in Pain, Postoperative by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 18 studies in Pain, Postoperative by Johnson & Johnson, this one is the 9th largest by enrollment, is the only one that started in 2009, is one of 8 in phase 3, and was the 17th registered.
Johnson & Johnson’s Pain, Postoperative studies by the year they started, since 2002.
2 of the studies testing tramadol in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07064993Arzu Esen TekeliEffects of Intraarticular Tramadol and Tramadol-Dexamethasone on Postoperative Pain After Knee Arthroscopy | 2027-02-26 |
| NCT07840183Northwestern UniversityEpidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies testing tramadol in Pain, Postoperative, from their registry updates:
Among Johnson & Johnson’s 18 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of extended release (ER) tramadol hydrochloride (HCl)/acetaminophen with immediate release (IR) tramadol HCl/acetaminophen in participants with moderate to severe (very serious, life threatening) postoperative pain.
This study is a randomized (study drug assigned by chance), multicenter (when more than 1 hospital or medical school team work on a medical research study), active-controlled, parallel group (each group of participants will be treated at the same time), double-blind (neither physician nor participant knows the treatment that the participant receives) study. The duration of the treatment will be 2 days and will be conducted in 4 periods: screening period (from 33 to 2 days before study drug administration to the first surgical incision), surgical period (to 1 day before study drug administration), qualification period (1 day) and double-blind treatment period (1 to 2 days). Participants will be randomly assigned to 2 groups: study drug treatment group (ER) and comparator treatment group (IR). Participants will be administered 2 tablets of ER tramadol HCl (75 milligram [mg])/acetaminophen (650 mg) along with 2 tablets of placebo matching to IR tramadol HCl/acetaminophen in study drug treatment group; and 2 tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) along with 2 tablets of placebo matching to ER tramadol HCl/acetaminophen in comparator treatment group respectively at 0, 12, 24 and 36 hours. Participants will also be administered 2 tablets of placebo matching to IR tramadol HCl/acetaminophen in study drug treatment group; and 2 tablets of IR tramadol HCl/acetaminophen in comparator treatment group respectively at 6, 18, 30 and 42 hours. Participants will be administered investigational product at 6-hour interval from the time of the first investigational product administration over 48 hours. Efficacy will be assessed using 11-point numeric rating scale (NRS). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram \[mg\])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.
Drug: Tramadol HCl/Acetaminophen ER
Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.
Drug: Tramadol HCl/Acetaminophen IR
Drug pages: Tramadol · Acetaminophen
2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
Also known as: Ultracet
Drug pages: Tramadol · Acetaminophen
2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
Also known as: Ultracet
Sum of Pain Intensity Difference (SPID) at Hour 48
The SPID is time-weighted sum of all observations of pain intensity difference (PID) collected at each measurement time point from Baseline to 48 hours. PID: Baseline pain intensity (PI) minus current PI; PI was assessed using 11-point numeric rating scale (NRS, 0=no pain to 10=worst pain imaginable). PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score for SPID at 48 hours (SPID48) ranges from -144 (worst) to 144 (best).
Time frame: Hour 48
Sum of Pain Intensity Difference (SPID) at Hour 6, 12 and 24
The SPID is time-weighted sum of all observations of PID collected at each measurement time point from Baseline to 24 hours. PID: Baseline PI minus current PI; PI was assessed using 11-point NRS, 0=no pain to 10=worst pain imaginable. PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score ranges from -18 (worst) to 18 (best) for SPID6, -36 (worst) to 36 (best) for SPID12 and -72 (worst) to 72 (best) for SPID24.
Time frame: Hour 6, 12, 24
Total Pain Relief (TOTPAR) Score
Pain relief was measured on a 5-point categorical scale of 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). TOTPAR was calculated as the time-weighted sum over all pain relief up to 48 hours. Total score ranges from 0 (worst) to 24 (best) for TOTPAR6, 0 (worst) to 48 (best) for TOTPAR12, 0 (worst) to 96 (best) for TOTPAR24 and 0 (worst) to 192 (best) for TOTPAR48.
Time frame: Hour 6, 12, 24, 48
Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID)
The SPRID is sum of SPID and TOTPAR. In SPID, PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<= 3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. In TOTPAR, pain relief score ranges from 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). Total score ranges from -18 (worst) to 42 (best) for SPRID6, -36 (worst) to 84 (best) for SPRID12, -72 (worst) to 168 (best) for SPRID24 and -144 (worst) to 336 (best) for SPRID48.
Time frame: Hour 6, 12, 24, 48
Time to the First Rescue Medication Administered Because of Insufficient Pain Relief
The time until administration of the first rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief after administration of the study drug was recorded. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular \[directly into muscle\] or intravenous injection \[directly into vein\]).
Time frame: Baseline up to Day 3
Number of Doses of Rescue Medication Administered Because of Insufficient Pain Relief
The frequency of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).
Time frame: Baseline up to Day 3
Dosage of Rescue Medication Administered Because of Insufficient Pain Relief
The dosage of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).
Time frame: Baseline up to Day 3
Patient Global Impression of Change (PGIC) Score
The PGIC was used to assess the degree of participant's overall improvement with treatment, and participants were instructed to assess how much the overall status had been improved after investigational product administration compared to baseline in 7 grades (1=Very much improved and B=Very much worsened).
Time frame: Day 3
| Milestone | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Started | 162 | 158 |
| Completed | 116 | 128 |
| Not completed | 46 | 30 |
| Withdrew: Adverse event | 16 | 5 |
| Withdrew: Withdrawal by subject | 20 | 16 |
| Withdrew: Protocol violation | 5 | 5 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Screening failure (drop-out) | 0 | 3 |
| Withdrew: Other | 2 | 0 |
The SPID is time-weighted sum of all observations of pain intensity difference (PID) collected at each measurement time point from Baseline to 48 hours. PID: Baseline pain intensity (PI) minus current PI; PI was assessed using 11-point numeric rating scale (NRS, 0=no pain to 10=worst pain imaginable). PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score for SPID at 48 hours (SPID48) ranges from -144 (worst) to 144 (best).
| Units on scale | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Sum of Pain Intensity Difference (SPID) at Hour 48 | 32.5 ± 30.7 | 37.2 ± 23.9 |
The SPID is time-weighted sum of all observations of PID collected at each measurement time point from Baseline to 24 hours. PID: Baseline PI minus current PI; PI was assessed using 11-point NRS, 0=no pain to 10=worst pain imaginable. PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<=3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. Total score ranges from -18 (worst) to 18 (best) for SPID6, -36 (worst) to 36 (best) for SPID12 and -72 (worst) to 72 (best) for SPID24.
| Units on scale | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Hour 6 | 3.6 ± 3.7 | 3.9 ± 3.3 |
| Hour 12 | 7.0 ± 7.8 | 8.1 ± 6.5 |
| Hour 24 | 14.6 ± 15.3 | 17.6 ± 12.7 |
Pain relief was measured on a 5-point categorical scale of 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). TOTPAR was calculated as the time-weighted sum over all pain relief up to 48 hours. Total score ranges from 0 (worst) to 24 (best) for TOTPAR6, 0 (worst) to 48 (best) for TOTPAR12, 0 (worst) to 96 (best) for TOTPAR24 and 0 (worst) to 192 (best) for TOTPAR48.
| Units on scale | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Hour 6 | 6.0 ± 4.8 | 6.8 ± 5.7 |
| Hour 12 | 12.5 ± 10.4 | 14.7 ± 11.1 |
| Hour 24 | 27.1 ± 21.3 | 31.0 ± 22.5 |
| Hour 48 | 55.6 ± 43.2 | 61.7 ± 44.5 |
The SPRID is sum of SPID and TOTPAR. In SPID, PI score ranges from 0-3 where 0=no pain and 3=severe pain. PI score of 0=NRS score of 0, PI score of 1=NRS score \>=1 and \<= 3, PI score of 2=NRS score of \>=4 and \<=6 and PI score of 3=NRS score of \>=7 and \<=10. In TOTPAR, pain relief score ranges from 0-4 (0=no change, 1=slight relief, 2=moderate relief, 3=fair relief, 4=pain resolved completely). Total score ranges from -18 (worst) to 42 (best) for SPRID6, -36 (worst) to 84 (best) for SPRID12, -72 (worst) to 168 (best) for SPRID24 and -144 (worst) to 336 (best) for SPRID48.
| Units on scale | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Hour 6 | 9.6 ± 7.3 | 10.9 ± 8.1 |
| Hour 12 | 19.6 ± 15.7 | 23.1 ± 15.2 |
| Hour 24 | 41.8 ± 31.6 | 49.1 ± 30.8 |
| Hour 48 | 85.9 ± 64.7 | 97.0 ± 61.0 |
The time until administration of the first rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief after administration of the study drug was recorded. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular \[directly into muscle\] or intravenous injection \[directly into vein\]).
| Minutes | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Time to the First Rescue Medication Administered Because of Insufficient Pain Relief | 1339 ± 710 | 1212 ± 853 |
The frequency of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).
| Doses | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Number of Doses of Rescue Medication Administered Because of Insufficient Pain Relief | 2.1 ± 1.9 | 1.4 ± 0.9 |
The dosage of the rescue medication (rescue medications are medicines that are administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation) because of insufficient pain relief was measured after administration of the study drug. Rescue medications allowed were oral or injection of tramadol HCl (intramuscular or intravenous injection).
| Milligram | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Dosage of Rescue Medication Administered Because of Insufficient Pain Relief | 50.0 ± 0.0 | 51.7 ± 9.1 |
The PGIC was used to assess the degree of participant's overall improvement with treatment, and participants were instructed to assess how much the overall status had been improved after investigational product administration compared to baseline in 7 grades (1=Very much improved and B=Very much worsened).
| Units on scale | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Patient Global Impression of Change (PGIC) Score | 2.71 ± 0.86 | 2.60 ± 0.80 |
Collected over Screening up to Day 3 or early withdrawal. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tramadol Hydrochloride (HCl)/Acetaminophen ER | — | 1/161 (0.6%) | 139/161 (86.3%) |
| Tramadol HCl/Acetaminophen IR | — | 0/153 (0%) | 129/153 (84.3%) |
| Event | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| Deep vein thrombosisVascular disorders | 1/161 | 0/153 |
| Event | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR |
|---|---|---|
| NauseaGastrointestinal disorders | 80/161 | 68/153 |
| VomitingGastrointestinal disorders | 45/161 | 37/153 |
| Haemoglobin decreasedInvestigations | 38/161 | 40/153 |
| ConstipationGastrointestinal disorders | 39/161 | 30/153 |
| PyrexiaGeneral disorders | 28/161 | 36/153 |
| PruritusSkin and subcutaneous tissue disorders | 33/161 | 26/153 |
| DysuriaRenal and urinary disorders | 27/161 | 24/153 |
| DyspepsiaGastrointestinal disorders | 11/161 | 20/153 |
| DizzinessNervous system disorders | 17/161 | 13/153 |
| HeadacheNervous system disorders | 15/161 | 9/153 |
| Age Continuous(Years) | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR | Total |
|---|---|---|---|
| Mean | 66.8 ± 6.4 | 67.5 ± 6.6 | 67.1 ± 6.5 |
| Sex: Female, Male(Participants) | Tramadol Hydrochloride (HCl)/Acetaminophen ER | Tramadol HCl/Acetaminophen IR | Total |
|---|---|---|---|
| Female | 155 | 138 | 293 |
| Male | 7 | 20 | 27 |
No study locations are listed for this record.
The record gives a start of Nov 2009, a primary completion of Jan 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Acetaminophen